QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.052597v1 306/3/1145    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tarazi, F. I. Articles by Zhang, K. Search for Related Content PubMed PubMed Citation Articles by Tarazi, F. I. Articles by Zhang, K.

NEUROPHARMACOLOGY

Long-Term Effects of Olanzapine, Risperidone, and Quetiapine on Ionotropic Glutamate Receptor Types: Implications for Antipsychotic Drug Treatment

Mailman Research Center, McLean Division of Massachusetts General Hospital, Belmont, Massachusetts (F.I.T., R.J.B., N.S.K., K.Z.); and Consolidated Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, Massachusetts (F.I.T., R.J.B., N.S.K., K.Z.)

Levels of ionotropic glutamate (Glu) N-methyl-D-aspartate (NMDA), -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA), and kainic acid (KA) receptors in rat forebrain regions were compared by quantitative in vitro receptor autoradiography after continuous treatment for 28 days with the atypical antipsychotics olanzapine, risperidone, and quetiapine, or vehicle controls. All three treatments significantly decreased NMDA binding in caudate-putamen (CPu; by 30, 34, and 26%, respectively) but increased AMPA receptor levels in same region (by 22, 30, and 28%). Olanzapine and risperidone, but not quetiapine, also reduced NMDA receptor labeling in hippocampal CA1 (21 and 19%) and CA3 (23 and 22%) regions. KA receptors were unaltered by any treatment in the brain regions examined. These findings suggest that the antipsychotic effects of olanzapine and risperidone may be mediated in part by NMDA receptors in hippocampus, and perhaps AMPA receptors in CPu. The findings also support the hypothesis that down-regulation of NMDA receptors by atypical antipsychotic agents in CPu contributes to their low risk of extra-pyramidal side effects. Inability of olanzapine, risperidone, and quetiapine to alter KA receptors suggests their minimal role in mediating the central nervous system actions of these drugs.

Address correspondence to: Dr. Frank I. Tarazi, Mailman Research Center, McLean Hospital, Harvard Medical School, 115 Mill St., Belmont, MA 02478. E-mail: ftarazi{at}hms.harvard.edu

This article has been cited by other articles:

				K Heard, S Krier, and N. Zahniser Administration of ziprasidone for 10 days increases cocaine toxicity in mice Human and Experimental Toxicology, June 1, 2008; 27(6): 499 - 503. [Abstract] [PDF]

				F. Fumagalli, A. Frasca, G. Racagni, and M. A. Riva Dynamic Regulation of Glutamatergic Postsynaptic Activity in Rat Prefrontal Cortex by Repeated Administration of Antipsychotic Drugs Mol. Pharmacol., May 1, 2008; 73(5): 1484 - 1490. [Abstract] [Full Text] [PDF]